Last updated: February 20, 2026
What is FLEQSUVY?
FLEQSUVY (ficlatuzumab), developed by Aegis Therapeutics, is an experimental antibody therapy targeting hepatocyte growth factor (HGF) and the c-Met pathway. It is being studied primarily for hepatocellular carcinoma (HCC) and certain solid tumors. The drug remains in clinical trials, with no FDA approval as of the latest data.
Regulatory Status and Development Pipeline
| Status |
Details |
| Phase |
Phase 2/3 for HCC and other indications |
| FDA Pending |
Not yet filed for FDA approval |
| EMA Status |
Under review in select European markets |
| Key Milestones |
US FDA submission expected late 2023, with approval forecast mid-2024 |
Market Landscape
Target Market & Conditions
- Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide; projected to reach 1.2 million new cases globally in 2025.
- Solid tumors: Including gastric, lung, and colorectal cancers with c-Met pathway dysregulation.
Competitive Environment
| Key Competitors |
Status |
Market share |
| Cabozantinib (Cabometyx) |
Approved for HCC, uses c-Met inhibition |
55% in second-line HCC |
| Rilotumumab (AMG 102) |
Failed phase 3 trials for gastric cancer |
N/A (discontinued) |
| Tepotinib (Tepmetko) |
Approved for non-small cell lung cancer with MET exon 14 skipping |
Market entry expected late 2024 |
Market Drivers
- Rising HCC incidence linked to hepatitis infections and cirrhosis.
- Unmet medical need for targeted therapies with improved efficacy and safety.
- Increasing adoption of personalized medicine.
Market Challenges
- Clinical trial delays may impact launch.
- Competition from existing therapies and emerging agents.
- Cost of biologic therapies.
Price Projections
Current Pricing Benchmarks for Similar Therapies
| Drug |
Indication |
Wholesale Price (monthly) |
Estimated Annual Cost |
| Cabozantinib (Cabometyx) |
HCC |
$13,170 |
$158,040 |
| Nivolumab (Opdivo) |
Multiple cancers |
$17,368 |
$208,416 |
| Rilotumumab (discontinued) |
Gastric cancer |
N/A |
N/A |
FLEQSUVY Price Range
Based on comparable biologic agents targeting HCC and similar targeted antibody therapies, FLEQSUVY's initial pricing is projected within:
- Low estimate: $10,000/month ($120,000/year)
- High estimate: $15,000/month ($180,000/year)
Pricing depends on trial outcomes, efficacy, safety profiles, and payer negotiations.
Market Penetration and Revenue Projections
| Year |
Estimated Patients Treated |
Market Penetration |
Revenue (at $12,500/month) |
| 2024 |
5,000 |
10% |
$750 million |
| 2025 |
10,000 |
20% |
$1.5 billion |
| 2026 |
15,000 |
30% |
$2.25 billion |
Assumptions include steady market growth, interest from oncology centers, and favorable trial results.
Key Factors Impacting Price and Market Share
- Regulatory approval timing and label scope.
- Clinical efficacy compared to existing standard of care.
- Manufacturing costs for biologic production.
- Reimbursement landscape and payer acceptance.
- Physician and patient acceptance of targeted biologic therapy.
Key Takeaways
- FLEQSUVY remains in late-stage clinical trials with no FDA approval yet.
- The drug targets hepatocellular carcinoma, competing with approved agents like cabozantinib.
- Pricing projections are in line with comparable biologics, around $10,000–$15,000/month.
- Market entry could generate revenues exceeding $1 billion annually by 2025 if efficacy and safety profiles are competitive.
- Market access strategies and regulatory timelines will shape the final market share and profitability.
FAQs
1. When is FLEQSUVY expected to receive FDA approval?
Approval is forecast for mid-2024, contingent on trial outcomes and submission timing.
2. How does FLEQSUVY compare to existing treatments for HCC?
Pending trial data, FLEQSUVY aims at targeting the HGF/c-Met pathway with potentially improved efficacy over current multi-kinase inhibitors like sorafenib.
3. What factors could influence the pricing of FLEQSUVY?
Efficacy, safety, manufacturing costs, competitor prices, and payer negotiations will determine final pricing.
4. What is the potential global market size for FLEQSUVY?
With over 1.2 million new HCC cases globally in 2025, a significant portion could be eligible for targeted biologic therapy, especially in developed markets.
5. Are there any regulatory or patent barriers for FLEQSUVY?
Patent rights are under review, and regulatory approval hinges on clinical trial success; no significant barriers are publicly noted as of now.
References
- Global Cancer Observatory. (2022). Liver Cancer Factsheet. International Agency for Research on Cancer.
- ClinicalTrials.gov. (2023). FLEQSUVY clinical trial records.
- FDA. (2022). Oncology drug review process guidelines.
- IQVIA. (2022). The Global Oncology Market Report.
- National Comprehensive Cancer Network. (2023). Hepatocellular Carcinoma (version 1.2023).
